TNFAIP3 (A20) and Susceptibility to Systemic Lupus Erythematosus

TNFAIP3 (A20) 与系统性红斑狼疮的易感性

• 批准号: 9353178
• 负责人: Patrick M Gaffney
• 金额: $ 65.36万
• 依托单位: OKLAHOMA MEDICAL RESEARCH FOUNDATION
• 依托单位国家: 美国
• 财政年份: 2009
• 资助国家: 美国
• 起止时间: 2009-08-07 至 2019-08-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/9353178
• 关键词: Alleles; Antigen-Antibody Complex; Attenuated; Autoantibodies; Autoantigens; Autoimmune Diseases; Autoimmunity; B-Lymphocytes; Binding; Bioinformatics; Celiac Disease; Cells; ChIP-seq; Chromatin; Chromatin Interaction Analysis by Paired-End Tag Sequencing; Chromatin Loop; Chronic Childhood Arthritis; Collection; Complement; Complex; Control Groups; Crohn' s disease; Data; Development; Enhancers; Ensure; Enzymes; Ethnic Origin; European; Funding; Gene Expression; Generations; Genes; Genetic; Genetic Enhancer Element; Genetic Materials; Genetic Transcription; Genomic Segment; Genomics; Genotype; Haplotypes; Health; Human; Human Genome; Immune System Diseases; Immune System and Related Disorders; Immune Tolerance; Impairment; Inflammatory; Insulin-Dependent Diabetes Mellitus; Interferons; Laboratories; Lead; Lupus; Methods; NF-kappa B; Nature; Nuclear Protein; Organ; Pathway interactions; Predisposition; Process; Production; Proteins; Psoriasis; Regulatory Element; Research; Research Infrastructure; Rheumatoid Arthritis; Risk; Role; Signal Pathway; Signal Transduction; Site; Sjogren' s Syndrome; Systemic Lupus Erythematosus; Systemic Scleroderma; Therapeutic; Transcriptional Regulation; Ubiquitin; Upstream Enhancer; Variant; Work; case control; clinically relevant; cohort; deep sequencing; disorder risk; experimental study; genetic variant; genome wide association study; genome-wide; insight; novel; novel therapeutics; promoter; protein complex; public health relevance; risk variant; success; transcription factor

DESCRIPTION (provided by applicant): Systemic lupus erythematosus (SLE) is characterized by a loss of immunologic tolerance to a multitude of self-antigens. Widespread innate and adaptive immune dysfunction includes interferon pathway dysregulation, high titer autoantibody production, and deficiencies in complement function and immune complex clearance. Inflammatory processes result in systemic end-organ damage. Despite decades of research, the underlying genetic basis of lupus is clearly complex and incompletely understood. Our laboratory identified TNFAIP3, a potent negative regulator of NF-κB signaling, as an SLE risk gene. In addition to SLE, genetic variants in the region of TNFAIP3 are associated rheumatoid arthritis, psoriasis, Crohn's disease, celiac disease, type 1 diabetes, Sjogren's syndrome, systemic sclerosis and juvenile rheumatoid arthritis suggesting that TNFAIP3 is a master regulator of autoimmunity. Therefore, clarifying the mechanisms that regulate TNFAIP3 expression and function are likely to have broad impact on human health. By fine mapping in SLE cohorts of multiple ethnicities and deep sequencing of TNFAIP3 risk haplotypes, we isolated two functional variants (rs148314165, rs200820567) responsible for association with SLE in the region of TNFAIP3. We showed that rs148314165 and rs200820567 (referred to as the TT>A variants) reside in an enhancer element that binds NF-κB and SATB1 enabling the interaction of the enhancer with the TNFAIP3 promoter through long-range DNA looping. Impaired binding of NF-κB to the enhancer harboring the TT>A risk allele, inhibits interaction of the enhancer with the TNFAIP3 promoter resulting in reduced A20 expression. These results reveal a novel functional mechanism by which rs148314165 and rs200820567 attenuate A20 expression and support a causal role for these variants in the predisposition to autoimmune disease. The primary scientific objective of this proposal will be to build upon these discoveries by elucidating mechanisms of TNFAIP3 transcriptional control that influence autoimmune disease risk. In the next funding period we will define the dynamic chromatin state for the TT>A enhancer and other SLE enhancers in primary B cells following stimulation using ChIP-sequencing (Aim 1), characterize the transcription factors and chromatin modifiers that assemble on the TT>A enhancer (Aim 2) and explore the functional effect of a putative novel enhancer 55 kb upstream of the TNFAIP3 promoter (Aim 3). All of these studies will be performed in the context of the SLE risk and nonrisk haplotypes to maximize the clinical relevance of our findings. These studies will serve to clarify new functional mechanisms that regulate TNFAIP3 expression and lay the groundwork for developing of rational therapeutics to restore homeostatic potency of TNFAIP3 in autoimmune disease.

描述(申请人提供)：系统性红斑狼疮(SLE)的特征是对多种自身抗原失去免疫耐受性。广泛存在的先天性和获得性免疫功能障碍包括干扰素途径失调、高滴度自身抗体的产生、补体功能和免疫复合物清除的缺陷。炎症过程会导致全身性终末器官损伤。尽管进行了数十年的研究，但狼疮的潜在遗传基础显然很复杂，而且还不完全清楚。我们的实验室发现，作为一种有效的NF-κB信号负调控因子，TNFAIP3是系统性红斑狼疮的危险基因。除系统性红斑狼疮外，TNFAIP3区域的基因变异还与类风湿性关节炎、牛皮癣、克罗恩病、乳糜泻、1型糖尿病、干燥综合征、系统性硬化症和幼年类风湿性关节炎有关，这表明TNFAIP3是自身免疫的主要调节因子。因此，阐明调控TNFAIP3表达和功能的机制可能对人类健康产生广泛的影响。通过对多种族SLE队列的精细定位和对TNFAIP3风险单倍型的深入测序，我们分离到了与TNFAIP3区域SLE相关的两个功能变异(rs148314165，rs200820567)。我们发现rs148314165和rs200820567(被称为TT&gt；A变异体)位于一个增强子元件中，该增强子元件能够结合NF-κB和SATB 1，使增强子通过远程DNA环与TNFAIP3启动子相互作用。核因子-κB与含有TT&gt；A风险等位基因的增强子的结合受损，抑制了增强子与TNFAIP3启动子的相互作用，导致A20表达减少。这些结果揭示了rs148314165和rs200820567减弱A20表达的新的功能机制，并支持这些变体在自身免疫性疾病易感性中的因果作用。这项提议的主要科学目标将是在这些发现的基础上再接再厉 通过阐明影响自身免疫性疾病风险的TNFAIP3转录调控机制。在下一个资助阶段，我们将定义TT&gt；A增强子和其他SLE增强子在原代B细胞中使用芯片测序后的动态染色质状态(目标1)，表征聚集在TT&gT；A增强子上的转录因子和染色质修饰物(目标2)，并探索TNFAIP3启动子上游55kb的假定新型增强子的功能效应(目标3)。所有这些研究都将在SLE风险和非风险单倍型的背景下进行，以最大限度地提高我们研究结果的临床相关性。这些研究将有助于阐明调节TNFAIP3表达的新的功能机制，并为开发合理的治疗方法以恢复TNFAIP3在自身免疫性疾病中的动态平衡效力奠定基础。